Real-world data comparison of time to next treatment for patients with HER2 positive metastatic breast cancer treated in the second line of therapy with fam-trastuzumab deruxtecan-nxki or ado-trastuzumab emtansine.

Authors: Vikram C. Gorantla, Anna Rui, Stephan B. Rosenfeld, Fred J. Kudrik, Anupama Vasudevan, Teena Sura, Mike Gart, Doug Kanovsky, Dawn Brenneman, Prateesh Varughese, Jeffrey A. Scott, Rushir J. Choksi, Robert B. Geller, Simon Blanc

Published: 2024-10-04

DOI: 10.1200/jco.2024.42.16_suppl.e13025

Source: Full article

---

Abstract

e13025